In many chronic conditions adherence to long-term treatment is a challenge, also for patients with eosinophilic esophagitis. Interventions, such as behavioral, educational and reminder interventions might improve treatment adherence. With this trial the investigators want to assess the effects of additional education in combination with more frequent follow up and patient reminders on adherence to treatment in adult patients with eosinophilic esophagitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
72
Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
Amsterdam UMC, location AMC
Amsterdam, Netherlands
RECRUITINGTreatment adherence at 12 weeks
Treatment adherence, defined as the proportion of subjects in both groups that meet a desired adherence rate of \> 80%, calculated by pill count adherence rate
Time frame: 12 weeks
Treatment adherence at 6 months
Treatment adherence, defined as the proportion of subjects in both groups that meet a desired adherence rate of \> 80%, calculated by pill count adherence rate
Time frame: 6 months
Treatment adherence at 12 months
Treatment adherence, defined as the proportion of subjects in both groups that meet a desired adherence rate of \> 80%, calculated by pill count adherence rate
Time frame: 12 months
Differences in self-reported treatment adherence measured by brief-IPQ
Differences in self-reported treatment adherence measured by brief-IPQ, a 9 item questionnaire where every item is assessed individually (0 to 10 response scale) except for 1 open-ended response item
Time frame: 12 weeks, 6 months and 12 months.
Differences in self-reported treatment adherence measured by BMQ
Differences in self-reported treatment adherence measured by BMQ, questionnaire with 2 subscales. Necessity subscale ranges from 5-20, where lower scores indicate low necessity beliefs. Concern scale ranges from 5-20 where lower scores indicate higher confidence in positive effects of medication.
Time frame: 12 weeks, 6 months and 12 months.
Differences in self-reported treatment adherence measured by 8-point MMAS
Differences in self-reported treatment adherence measured by 8-point MMAS. Total scores range between 0 to 8, where a higher score indicates higher treatment adherence
Time frame: 12 weeks, 6 months and 12 months.
Differences in self-reported treatment adherence measured by MARS questionnaire
Differences in self-reported treatment adherence measured by MARS questionnaire 5. Scores range between 1-25, where a higher score indicates higher reported treatment adherence
Time frame: 12 weeks, 6 months and 12 months.
Change in clinical symptoms measured by DSQ questionnaire
Change in clinical symptoms measured by DSQ questionnaire. Total score range from 0 to 84, where higher scores indicate more symptoms
Time frame: 12 weeks, 6 months and 12 months
Change in clinical symptoms measured by SDI questionnaire
Change in clinical symptoms measured by SDI questionnaire. Total scores of the SDI ranges between 0 to 9, where higher scores indicate more symptoms.
Time frame: 12 weeks, 6 months and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.